
A Nigerian pharmaceutical manufacturer, AMA Medical Manufacturing, is expanding its operations into the Caribbean following a $32 million agreement involving Nigeria, Barbados and the African Export-Import Bank (Afreximbank) to establish a pharmaceutical factory in the region.
The proposed facility will manufacture intravenous (IV) fluids, with an annual production capacity of 12 million units. Production is expected to begin in 2029, according to Samuel Adeoye, Vice President of Partnerships at Pan-African, who disclosed the agreement in a LinkedIn post.
The deal marks an international expansion for the Nigerian manufacturer, with development financing supporting the establishment of pharmaceutical production capacity outside Africa. Brandspur Business News reports that the project also highlights the growing potential of African pharmaceutical companies to participate in international manufacturing and supply chains.
However, the expansion comes against the backdrop of Nigeria’s continued dependence on imported medicines. Adeoye noted that more than 70 per cent of medicines consumed in the country are still sourced from abroad, leaving patients, pharmacies and healthcare providers exposed to import costs and distribution expenses.
The dependence has implications for ordinary Nigerians, particularly patients who have to contend with the cost of prescribed medicines. Pharmacies and healthcare facilities also rely on supply chains that can be affected by import-related expenses.
Adeoye acknowledged the significance of taking Nigerian pharmaceutical manufacturing expertise to international markets but raised questions about the pace of investment in domestic infrastructure.
He pointed to gaps in local procurement, medicine distribution, pharmacy networks and reimbursement systems, arguing that manufacturing capacity alone would not guarantee affordable access to medicines.

According to him, locally produced medicines must be supported by efficient systems capable of moving products from factories to patients at affordable prices.
The proposed Caribbean factory is expected to add to the international manufacturing footprint of AMA Medical Manufacturing when production begins in 2029. However, the agreement has also drawn attention to the need for stronger domestic pharmaceutical infrastructure to ensure that increased manufacturing capacity translates into better medicine availability and affordability for Nigerians.





